Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis

What Was Tested

Researchers studied Vasopressin and Desmopressin in this clinical trial publication.

Cirrhosis frequently affects multiple components of hemostasis.

Reversal of the coagulopathy of these patients is frequently required in case of bleeding episodes, or as prophylaxis before invasive procedures.

Although 1-deamino-8-D-arginine vasopressin (DDAVP) is widely used as a pro-hemostatic agent in patients with cirrhosis, it is unclear whether DDAVP truly enhances hemostasis in these patients.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

Plasma was collected prior to and at 1, 3, 6, and 24 h after DDAVP administration.

Levels of Von Willebrand factor (VWF), VWF propeptide, factor VIII (FVIII), and ADAMTS13 were measured in all plasma samples, whereas VWF multimers and functional VWF-dependent platelet adhesion were determined in the samples pre- and 1 h after DDAVP administration.

What Was Measured

The subject headings attached to it are ADAM Proteins, ADAMTS13 Protein, Biomarkers, Deamino Arginine Vasopressin, Factor VIII, Hemophilia A and Hemostasis.

The authors tagged it with the keywords cirrhosis, desmopressin, haemophilia, platelet and von Willebrand factor.

What This Means in Plain Language

This is a clinical trial of Vasopressin and Desmopressin.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Liver international : official journal of the International Association for the Study of the Liver), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.